Clofibrate for unconjugated hyperbilirubinemia in neonates: a systematic review.
OBJECTIVE
To evaluate the effect of clofibrate for unconjugated hyperbilirubinemia in neonates.


METHODS
A systematic review with meta-analysis of randomized controlled trials or quasi-randomized controlled trials was conducted to evaluate the clofibrate treatment in neonates with unconjugated hyperbilirubinemia. We followed the guidelines from the Cochrane review group and the PRISMA statement.


RESULTS
Of 148 studies identified, a total of 13 studies on 867 infants were included. A single oral administration of clofibrate was associated with decreased need of phototherapy (RR:.38, 95% CI: 0.21 to 0.68), shortened duration of phototherapy (mean duration: 23.88 h, 95% CI: 33.03 to -14.72 h) and reduced peak total serum bilirubin (mean duration: -1.62 mg/dL, 95% CI: 2.13 to -1.11 mg/dL). These effects were especially obvious in term infants and infants without hemolytic diseases. Data regarding mortality or kernicterus were not available from included studies.


CONCLUSIONS
Clofibrate may have short-term benefits for the infants with hyperbilirubinaemia, especially for population of term infants and infants without hemolytic diseases. Large RCTs with long-term followup are required to verify the safety of clofibrate and assess its long-term effects.
Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, China.
Tao
T
Xiong
Dapeng
D
Chen
Zhoujin
Z
Duan
Yi
Y
Qu
Dezhi
D
Mu
D001663:Bilirubin / Q000097:blood*; D002994:Clofibrate / Q000627:therapeutic use*; D006801:Humans; D051556:Hyperbilirubinemia, Neonatal / Q000188:drug therapy* / Q000628:therapy; D007231:Infant, Newborn; D010789:Phototherapy; D016896:Treatment Outcome
D002994:Clofibrate; D001663:Bilirubin